In pancreatic cancer, where CD44 expression correlates with poor prognosis, intravenous delivery of an anti-CD44 monoclonal antibody H4C4 has been shown to completely inhibit tumor growth and metastasis in two different pancreatic xenograft models. Here, CD44 is linked to familial pancreatic carcinoma.